Dogwood Therapeutics may Trap Short Sellers Following Positive Announcement

January 24, 2025

DENVER, Colo., Jan 24, 2025 (247marketnews.com)- Dogwood Therapeutics (NASDAQ:DWTX) reached a new 52-week high of $29.28, yesterday, before retreating to close at $13.35. The subsequent pullback attracted short sellers. However, with Dogwood trading higher in premarket this morning, it appears some short traders may have been caught off guard.
The move follows Dogwood’s announcement that dosing for its Phase 2b clinical trial, HALT-CINP (Halneuron Treatment of Chemotherapy-Induced Neuropathic Pain). The trial is expected to begin in the first quarter of 2025. The trial will evaluate Halneuron for the treatment of neuropathic pain linked to chemotherapy-induced neuropathy (CINP).
Dr. R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer at Dogwood Therapeutics, explained, “Chemotherapy is effective, but it presents significant challenges due to common side effects like fever, fatigue, infection, hair loss, neuropathy, and pain. Research indicates that one in three patients treated with chemotherapy drugs such as taxanes and platinum-based agents develop chronic painful neuropathy. There are no approved treatments for this condition, and existing off-label analgesics are often ineffective. Additionally, market data suggests that about one in three cancer patients are treated with opioids.”
The announcement sparked renewed interest in Dogwood, as the company positions Halneuron as a potential game-changer.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (DWTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.